Abstract 2058P
Background
Strategies targeting oral anticancer drug (OAD) waste are required to improve sustainability and affordability of these expensive treatments frequently remaining unused by patients. This study aims to quantify waste reduction, cost-savings and environmental impact obtained by redispensing unused OADs compared to standard practice of disposal.
Methods
A prospective, single-arm intervention study was conducted in four Dutch hospitals. Eligible patients were ≥18 years, diagnosed with cancer and prescribed an OAD. During twelve months, participants received OAD packages sealed with a time-temperature indicator. If unused, OADs were returned to the pharmacy where quality was assured by checking authenticity, shelf life and storage temperature. OADs of verified quality were redispensed to other patients. Waste reduction was expressed as the percentage returned OADs that were redispensed. Mean annual cost-savings per patient were costs of redispensed OADs minus operational expenses from a healthcare perspective. Impact on environmental indicators was assessed via a cradle-to-grave Life Cycle Assessment. Patient subgroups associated with positive cost-savings were identified with multiple logistic regression. Scenarios analyses on the effect of optimized quality assurance and patient population selection was performed.
Results
1,071 patients participated, median age 70 years (IQR: 62–75) and 41.9% female. 224 OAD packages (1.7%) of 128 patients (12.0%) were redispensed (2.4% of total drug costs), reducing waste by 68.1% and providing mean annual cost-savings of €576 per patient (95% CI: 444–709). Optimizing quality assurance and targeting patient subgroups (< 24 months OAD use/using targeted therapies) could increase mean annual cost-savings up to €1,348 (1,039 – 1,697) per patient. Waste reduction was associated with mean annual environmental benefits of >1 kg CO2 per patient, but only with an optimized quality assurance procedure a net beneficial impact on environmental indicators was achieved.
Conclusions
Redispensing unused OADs reduces waste substantially, generates cost-savings and can benefit environmental impact, improving sustainability and affordability of cancer treatment.
Clinical trial identification
WHO International Clinical Trials Registry Platform (ICTRP) Identifier: NL9208.
Editorial acknowledgement
Legal entity responsible for the study
ROAD-study group.
Funding
Netherlands Organisation for Health Research and Development ZonMw (grant 848018008).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2116P - Preoperative body mass index, waist circumference, and mortality after major cancer surgery: A nationwide cohort study in South Korea
Presenter: Jiwon Yoon
Session: Poster session 06
2117P - Dietary patterns and clinical outcomes in patients with lung cancer: What needs to change
Presenter: Imanuely Borchardt
Session: Poster session 06
2118P - Refeeding syndrome: A prospective analysis in adults admitted to an oncology hospital
Presenter: Filipe Gonçalves
Session: Poster session 06
2119P - The prognostic impact of nutritional assessment and scores in advanced gastric cancer
Presenter: Sara Torresan
Session: Poster session 06
2120P - Nutritional deficiency post gastric cancer surgery
Presenter: Abay Makishev
Session: Poster session 06
2121P - Association between nutritional status and adverse events in gastrointestinal cancer patients undergoing outpatient chemotherapy in Japan
Presenter: Naoko Sato
Session: Poster session 06
2122P - Clinical significance of oncology patients’ nutritional status assessment
Presenter: Efthymios Kostaridis
Session: Poster session 06
2123P - Value of immuno-nutritional scores in the prognosis of hospitalised patients with lung cancer
Presenter: Jesús López
Session: Poster session 06
2124P - The impact of NUTRItional status at first medical oncology visit ON Clinical Outcomes: The NUTRIONCO study
Presenter: Maurizio Muscaritoli
Session: Poster session 06
2125P - Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study
Presenter: Alessio Cortellini
Session: Poster session 06